Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Angionetics To Present At 2015 LD Micro Invitational Investor Conference On Business And Generx® Phase 3 Clinical Development Activities Angiogenic Cardiovascular Gene Therapy: The Beauty of...
Angionetics Presents at the 2015 American Society of Gene & Cell Therapy Conference On Generx® Angiogenic Phase 3 Gene Therapy Program PR Newswire SAN DIEGO, May 15, 2015 SAN DIEGO, May 15...
Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx® Clinical Development Activities PR Newswire SAN DIEGO, May 11, 2015 SAN DIEGO, May 11, 2015 /PRNewswire/...
Angionetics Initial Equity Funding to Advance as Independent Company to Develop and Commercialize Phase 3 Generx® Gene Therapy Product Candidate PR Newswire SAN DIEGO, April 13, 2015 SAN DIEGO...
Taxus Cardium Announces Agreement With Dr. Reddy's Laboratories To Co-Develop, Market & Sell Generx Angiogenic Microvascular Gene Therapy In Certain International Markets PR Newswire SAN...
Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum New Insights, Discoveries...
Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor Jiayue Zhang, John Wallace, U.S. Equity Trading Services Executive, And Wei-Wei Zhang, International Gene Therapy...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 34375 | 1.0E-6 | CS |
| 52 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 15446 | 1.0E-6 | CS |
| 156 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 17293 | 2.091E-5 | CS |
| 260 | -0.109999 | -99.9990909091 | 0.11 | 0.18 | 1.0E-6 | 353736 | 0.05351617 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
